Portal de Periódicos da CAPES

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

2021; Mary Ann Liebert, Inc.; Volume: 31; Issue: 7 Linguagem: Inglês

10.1089/thy.2020.0322

1557-9077

Christine Dierks, Jochen Seufert, Konrad Aumann, Juri Ruf, Claudius Klein, Selina Kiefer, Michael Rassner, Melanie Boerries, A. Zielke, Paul La Rosée, Philipp T. Meyer, Matthias Kroiß, Christian Weißenberger, Tilmann Schumacher, Patrick Metzger, Harald Weiss, Constantin Smaxwil, Katharina Laubner, Justus Duyster, Nikolas von Bubnoff, Cornelius Miething, Oliver Thomusch,

Cancer Immunotherapy and Biomarkers

Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) despite extensive multimodal therapy. These tumors are highly proliferative, with frequently increased tumor mutational burden (TMB) compared with differentiated thyroid carcinomas, and elevated programmed death ligand 1 (PD-L1) levels. These tumor properties implicate responsiveness to antiangiogenic and antiproliferative multikinase inhibitors such as lenvatinib, and immune checkpoint inhibitors such as pembrolizumab.